Cargando…

Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)

BACKGROUND: The endogenous opioid system is a fundamental regulator of mood in humans. Previously reported clinical trials have demonstrated the efficacy of the investigational agent buprenorphine/samidorphan (BUP/SAM) combination, an opioid-system modulator, for the adjunctive treatment of major de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zajecka, John M, Stanford, Arielle D, Memisoglu, Asli, Martin, William F, Pathak, Sanjeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459143/ https://www.ncbi.nlm.nih.gov/pubmed/31040679 http://dx.doi.org/10.2147/NDT.S199245

Ejemplares similares

Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2019)

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies
por: Fava, Maurizio, et al.
Publicado: (2018)

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
por: Correll, Christoph U, et al.
Publicado: (2022)

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021)

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study
por: Sanacora, Gerard, et al.
Publicado: (2017)

A Review of Samidorphan: A Novel Opioid Antagonist
por: Chaudhary, Amna Mohyud Din, et al.
Publicado: (2019)

The Facts and Fiction of Olanzapine-Samidorphan Fixed Dose Combination
por: Das, Nileswar, et al.
Publicado: (2022)

Yoga as an Adjunctive Intervention to Medication-Assisted Treatment with Buprenorphine+Naloxone
por: Lander, Laura, et al.
Publicado: (2017)

Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age
por: Kumar, Vipul, et al.
Publicado: (2019)

Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate
por: Sun, Lei, et al.
Publicado: (2019)

Efficacy of physical activity in the adjunctive treatment of major depressive disorders: preliminary results
por: Pilu, Alessandra, et al.
Publicado: (2007)

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
por: Sun, Lei, et al.
Publicado: (2020)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review
por: Serafini, Gianluca, et al.
Publicado: (2018)

Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
por: Sun, Lei, et al.
Publicado: (2019)

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
por: Cunningham, Jacobi I, et al.
Publicado: (2019)

T35. A PHASE 3, MULTICENTER STUDY TO ASSESS THE 1-YEAR SAFETY AND TOLERABILITY OF A COMBINATION OF OLANZAPINE AND SAMIDORPHAN IN PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM THE ENLIGHTEN-2-EXTENSION
Publicado: (2020)

A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
por: Srisurapanont, Manit, et al.
Publicado: (2021)

In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations
por: Tan, Laura A, et al.
Publicado: (2022)

Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
por: Peng, Zhenlei, et al.
Publicado: (2023)

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
por: Mahableshwarkar, Atul R, et al.
Publicado: (2015)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Measuring Response to Adjunctive Therapy Among Individuals with Major Depressive Disorder
por: Forma, Felicia, et al.
Publicado: (2022)

Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials
por: Rehan, Syeda Tayyaba, et al.
Publicado: (2022)

Small steps forward: Adjunctive therapy for T1D
por: Bloomgarden, Zachary, et al.
Publicado: (2022)

Depression-Like Effect of Prenatal Buprenorphine Exposure in Rats
por: Hung, Chih-Jen, et al.
Publicado: (2013)

Modeling buprenorphine reduction of fentanyl-induced respiratory depression
por: Olofsen, Erik, et al.
Publicado: (2022)

Buprenorphine
por: Mazurek, Jaroslaw, et al.
Publicado: (2014)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
por: Sun, Lei, et al.
Publicado: (2021)

Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
por: Sun, Lei, et al.
Publicado: (2018)

Effect of buprenorphine as an adjunct with plain local anesthetic solution in supraclavicular brachial plexus block on quality and duration of postoperative analgesia
por: Patil, Surekha, et al.
Publicado: (2015)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist
por: Shram, Megan J., et al.
Publicado: (2015)

Postoperative respiratory depression in patients on sublingual buprenorphine: a retrospective cohort study for comparison between postoperative continuation and discontinuation of buprenorphine
por: Komatsu, Ryu, et al.
Publicado: (2022)

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
por: Jones, Aksana K., et al.
Publicado: (2020)

Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
por: Warnes, Harriet, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hcob7d03vmajqehtc35l84rovh